Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MNKD
stocks logo

MNKD

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
77.82M
+7.51%
--
--
79.53M
+13.48%
--
--
82.92M
+8.01%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for MannKind Corporation (MNKD) for FY2025, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by -12.05%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.1%
In Past 3 Month
Stock Price
Go Down
down Image
-12.05%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.80 USD with a low forecast of 7.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 3.905
sliders
Low
7.00
Averages
9.80
High
12.00
up Image0
Current: 3.905
sliders
Low
7.00
Averages
9.80
High
12.00
H.C. Wainwright
Buy
initiated
$9
2025-07-16
New
Reason
H.C. Wainwright
Price Target
$9
2025-07-16
New
initiated
Buy
Reason
H.C. Wainwright assumed coverage of MannKind with a Buy rating and $9 price target. The firm views the company's pipeline as largely overlooked at current share levels. MannKind's valuation does not balance the potential headwinds with potential tailwinds on the Tyvaso royalty, the analyst tells investors in a research note.
Wells Fargo
Tiago Fauth
Buy
Initiates
$9
2024-12-20
Reason
Wells Fargo
Tiago Fauth
Price Target
$9
2024-12-20
Initiates
Buy
Reason
RBC Capital
Gregory Renza
Hold
to
Buy
Upgrades
$7 → $10
2024-12-19
Reason
RBC Capital
Gregory Renza
Price Target
$7 → $10
2024-12-19
Upgrades
Hold
to
Buy
Reason
RBC Capital upgraded MannKind to Outperform from Sector Perform with a price target of $10, up from $7.
Leerink Partners
Faisal Khurshid
Buy
Initiates
$8
2024-09-09
Reason
Leerink Partners
Faisal Khurshid
Price Target
$8
2024-09-09
Initiates
Buy
Reason
Oppenheimer
Steven Lichtman
Buy
Maintains
$10 → $12
2024-08-28
Reason
Oppenheimer
Steven Lichtman
Price Target
$10 → $12
2024-08-28
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for MannKind Corp (MNKD.O) is 18.84, compared to its 5-year average forward P/E of 9.42. For a more detailed relative valuation and DCF analysis to assess MannKind Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.42
Current PE
18.84
Overvalued PE
70.25
Undervalued PE
-51.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.40
Undervalued EV/EBITDA
-38.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.46
Current PS
0.00
Overvalued PS
10.93
Undervalued PS
3.99

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 337.78% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MNKD News & Events

Events Timeline

(ET)
2025-05-08
08:13:00
MannKind reports Q1 EPS 7c vs 6c last year
select
2025-02-26 (ET)
2025-02-26
16:58:29
MannKind reports Q4 EPS 3c, consensus 3c
select
2024-12-18 (ET)
2024-12-18
06:11:36
MannKind announces exchange of convertible notes for stock, cash
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-24Yahoo Finance
MannKind (MNKD) Presents Pediatric Insulin Trial Data

  • MannKind Corporation's Presentation: MannKind Corporation will present its inhaled insulin product, Afrezza, at the American Diabetes Association’s 85th Scientific Sessions, with Dr. Michael J. Haller discussing results from the INHALE-1 clinical trial for children and adolescents.

  • Future Plans: The company plans to release topline results from the pediatric study in Q2 2025 and aims to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza by mid-2025.

Preview
3.0
06-11Benzinga
Top 3 Health Care Stocks That May Rocket Higher This Quarter

  • Oversold Stocks in Healthcare: The healthcare sector has several oversold stocks with low RSI values, indicating potential buying opportunities for undervalued companies like MannKind Corp, SS Innovations International, and INVO Fertility Inc.

  • Boxabl Investment Opportunity: Boxabl is attracting significant interest for its foldable tiny homes and is raising $1 billion to scale production, offering investors a chance to buy shares at $0.80 each, amidst a growing demand for affordable housing solutions.

Preview
5.0
06-11NASDAQ.COM
Insider Sale: Director at $MNKD Sells 64,085 Shares

  • Insider Trading Activity: Steven B. Binder, a director at $MNKD, sold 64,085 shares for approximately $256,340, representing about 6.5% of his holdings, with no insider purchases reported in the last six months.

  • Institutional and Analyst Insights: In the last quarter, 114 institutional investors increased their positions in $MNKD while 121 decreased theirs; analysts have issued 1 buy rating and no sell ratings on the stock recently.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MannKind Corp (MNKD) stock price today?

The current price of MNKD is 3.905 USD — it has increased 0.13 % in the last trading day.

arrow icon

What is MannKind Corp (MNKD)'s business?

MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.

arrow icon

What is the price predicton of MNKD Stock?

Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.80 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MannKind Corp (MNKD)'s revenue for the last quarter?

MannKind Corp revenue for the last quarter amounts to 78.35M USD, increased 18.25 % YoY.

arrow icon

What is MannKind Corp (MNKD)'s earnings per share (EPS) for the last quarter?

MannKind Corp. EPS for the last quarter amounts to 0.04 USD, increased 33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for MannKind Corp (MNKD)'s fundamentals?

The market is revising Downward the revenue expectations for MannKind Corporation (MNKD) for FY2025, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by -12.05%.
arrow icon

How many employees does MannKind Corp (MNKD). have?

MannKind Corp (MNKD) has 407 emplpoyees as of July 18 2025.

arrow icon

What is MannKind Corp (MNKD) market cap?

Today MNKD has the market capitalization of 1.19B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free